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ABSTRACT
Objective: To report the operative technique, oncologic
and therapeutic outcomes, and learning curve from our
initial series of over 140 patients treated by robotic radical
prostatectomy.
Methods: Between January 2003 and May 2005, 143 pa-
tients with clinically localized prostate cancer underwent a
robotic radical prostatectomy. Prospective data collection
included patient age, body mass index (BMI), clinical T
stage, biopsy Gleason score, and prostate-specific antigen
(PSA). Operative outcome measures included operative
time, estimated blood loss (EBL), and complications. Post-
operative outcomes were length of hospital stay, catheter
duration, pathology, margin status, biochemical recur-
rence, and return of continence.
Results: Mean operative time was 241 minutes with an
EBL of 274 mL. Five patients (3%) required conversion to
open surgery. The average hospitalization was 1.8 days,
and Foley catheters were removed after 8.9 days. Twenty-
four of 141 men (17%) had a positive surgical margin, with
a decrease from 23% in the first half of our experience to
11% in the latter half. Patients with an extracapsular ex-
tension had a significantly higher positive surgical margin
rate than did those with organ-confined disease (47% vs
15%). Over 40% of the positive margins were located
posteriorly. At a mean follow-up of 11 months, 96% of
patients had a PSA0.2 ng/mL. The median time to com-
plete continence was 3.5 months, and over 95% of pa-
tients were fully continent at 1 year.
Conclusion: Robotic radical prostatectomy is an effective
treatment modality for clinically localized prostate cancer.
Although a learning curve needs to be overcome, patients
experienced benefits in convalescence with early onco-
logic and functional outcomes comparable to those of the
open approach. Longer-term results are needed; however,
patient outcomes in our series are encouraging.
Key Words: Robotic radical prostatectomy, Prostate can-
cer, Urologic oncology, Operative techniques, Learning
curve.
INTRODUCTION
Since the initial description by Walsh and Donker in 1982
regarding the anatomic basis for erectile function, urolo-
gists have continuously explored technical advances that
would improve both the oncologic and quality of life
outcomes following radical prostatectomy.1 Anatomical
nerve-sparing methods have become mainstream practice
with resultant improvements in erectile function rates fol-
lowing what was once considered a morbid procedure.2
Although some interval modifications have been achieved
in the radical retropubic prostatectomy operation, the next
most significant advancement in surgical technique has
been the introduction of laparoscopy. In the late 1990s,
Guillonneau and Vallancien3 introduced laparoscopic rad-
ical prostatectomy as a viable surgical alternative for treat-
ing prostate cancer. Subsequently, several centers have
gone on to incorporate laparoscopic prostatectomy into
their surgical armamentarium with successful outcomes.4,5
Having set the stage for laparoscopy in the surgical treat-
ment of prostate cancer, urologists then sought to improve
upon such techniques with the use of robotics and the
implementation of robotic radical prostatectomy.6,7
Throughout the evolution of technology and treatment
strategies, the urologic community has stringently empha-
sized the need to demonstrate both oncologic and thera-
peutic efficacy of procedures. The acceptance of changes
in surgical technique has always been predated by de-
monstrable evidence from multiple institutions, regarding
both the clinical and pathologic criteria that are essential
for the successful treatment of prostate cancer. As such,
we have entered the robotic age in the treatment of pros-
tate cancer with encouraging reports from a few centers of
excellence.8–11
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SCIENTIFIC PAPERHere then, we hope to further diversify the experience in
robotic prostatectomy and enrich the confidence of treat-
ing urologists by reporting our operative technique, on-
cologic and therapeutic outcomes, and learning curve
from our initial series of over 140 consecutive patients
treated by robotic radical prostatectomy.
METHODS
Patient Selection
Between January 2003 and May 2005, 174 consecutive
patients with clinically localized prostate cancer under-
went a robotic radical prostatectomy performed by 2 sur-
geons (DSS and DS) at the New York-Presbyterian Hos-
pital. Thirty-one patients with a follow-up period of less
than 3 months were excluded from analysis in this study.
The remaining 143 patients were then analyzed for the
purposes of assessing outcomes. All patients had biopsy
proven adenocarcinoma of the prostate and were staged
according to the 2002 American Joint Committee on Can-
cer (AJCC) classification.12
Operative Technique
All patients underwent a robotic radical prostatectomy
with the da Vinci surgical system (Intuitive Surgical Inc.,
Sunnyvale, CA). The procedure was performed as de-
scribed by Menon et al11 with a few modifications.
Briefly, following induction of general endotracheal anes-
thesia, the patient was placed in the lithotomy position
with a steep Trendelenberg. The abdominal and groin
areas were prepped and draped, intravenous antibiotics
were administered before skin incision, and a 20-F, 30-cc
urethral catheter was placed. A 1.5-cm incision was made
to the left of the umbilicus, and a Veress needle was used
to insufflate the abdomen with CO2 to a pressure of 15cm
H20. A 10/12-mm trocar for the camera was placed at the
umbilicus, two 8-mm trocars for the robotic arms were
placed just lateral to the medial umbilical ligaments, a
5-mm suction port was introduced to the right of the
umbilicus, and 10/12-mm and 5-mm trocars were intro-
duced 2 fingerbreadths above the iliac crest on the pa-
tient’s right and left side, respectively. Overall, 6 ports
were used, and the da Vinci robot was docked.
Starting with a 30
o angle-up lens, the medial umbilical
ligaments were incised up the anterior abdominal wall
allowing cephalad reflection of the bladder and entry into
the space of Retzius. The adipose tissue overlying the
endopelvic fascia was cleared. The lens was changed to a
0
o angle, and the endopelvic fascia was opened in a
cautery-free manner to expose the apex of the prostate.
The levator muscles were swept posterolaterally, and the
puboprostatic ligaments were sharply divided to gain fur-
ther length beyond the apex of the prostate. The superfi-
cial and deep dorsal veins were ligated with a 0-vicryl
stitch, and a second 0-vicryl stitch was then placed for
back bleeding over the anterior surface of the prostate.
The 30
o angle-down lens was used for the bladder neck
dissection. The anterior bladder neck was divided, and the
ureteral orifice position and presence of a median lobe
were assessed, and then the posterior bladder neck was
divided. The vas deferens and seminal vesicles were then
identified. The vasa were divided and the seminal vesicles
were dissected in a cautery-free manner to avoid potential
injury to the neurovascular bundles. The posterior layer of
Denonvillier’s fascia was divided allowing for identifica-
tion of perirectal fat, which served as a guide between the
prostate and rectum. To optimize nerve sparing, all pros-
tatic pedicles were clipped and sharply divided without
using electrocautery. The lateral prostatic fascia was in-
cised on each side allowing the neurovascular bundles to
fall posterolaterally, and a bilateral nerve-sparing proce-
dure was performed when possible.
The neurovascular bundle was released distally to the
level of the urethra and prostatic apex. At this point, the
only remaining attachments of the prostate were the dor-
sal vein complex (DVC) and the urethra. The DVC and
urethra were then divided rendering the prostate free, and
the specimen was placed in a 10-mm endocatch bag.
Intraoperative frozen sections was used judiciously to
help decrease the incidence of positive surgical margins.
The urethrovesical anastomosis was performed in a run-
ning fashion by using a double-arm 2–0 Monocryl suture.
An 18-Fr, 10-mL urethral catheter was placed and irrigated
to ensure a water-tight anastomosis. A bilateral pelvic
lymph node dissection was performed following comple-
tion of the urethrovesical anastomosis in patients with a
greater than 2% chance of positive lymph nodes as ob-
tained from the Partin predictive tables. Borders of the
node dissection were the external iliac vein anteriorly,
obturator nerve posteriorly, bifurcation of common iliac
artery superiorly, and Cooper’s ligament inferiorly. A #10
flat JP drain was placed into the pelvis and brought out
through the left-side 5-mm port. The da Vinci robot was
then undocked, all trocars were removed under direct
vision, and the specimen was removed through the cam-
era port. The fascia at the extraction site was closed with
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Follow-up
Patients were seen approximately 1 week postoperatively
for catheter removal. Cystograms were not routinely ob-
tained before catheter removal. Postoperative PSA values,
urinary continence, and erectile function were evaluated 6
weeks postoperatively, every 3 months for the first year,
every 6 months for the second year, and yearly thereafter.
Data collection, Outcomes, and Statistical Analysis
Before surgery, all men were evaluated with the following
data recorded: age, BMI, clinical T stage, biopsy Gleason
score, and prostate-specific antigen (PSA). Operative out-
come measures included operative time, estimated blood
loss (EBL), and complications. Postoperative outcomes
were length of hospital stay, catheter time, pathology,
margin status, biochemical recurrence, and return of con-
tinence. The chi-square (
2) log-rank test with the Yates
correction factor and the unpaired 2-tailed Student t test
were used to compare variables between the first and
second 70 patients in our series.
RESULTS
The demographic data of the patient population are sum-
marized in Table 1. Table 2 outlines the operative data
from our series of patients. The mean operative time was
241 minutes (range, 120 to 540), with a decrease of over
100 minutes when comparing our initial series of 70 with
our more recent 70 patients (318 vs 209, P0.001). The
mean estimated blood loss (EBL) was 274 mL (range, 10 to
800), with a significant decrease in our more recent series
of patients (387 vs 155, P0.001). In 127 men, data re-
garding nerve sparing were available. One hundred and
nine of 127 men (86%) had a bilateral nerve-sparing op-
eration, whereas 13/127(10%) had unilateral nerve-spar-
ing, and 5/127(4%) had bilateral nerve resections. Sixty-six
of the last 70 patients (94%) had bilateral nerve-sparing
operations. Two individuals underwent robotic-assisted
genitofemoral nerve grafts. Five patients (3%) had a con-
version to open surgery for bleeding,1 large intravesical
median lobes,2 adherence to the rectum,1 and robot mal-
function.1 Only 1 of our last 70 patients (1%) required an
open conversion.
Table 3 summarizes the postoperative data. The mean
hospital stay was 1.8 days (range, 1 to 10). Of our most
recent 70 patients, 65 (93%) were discharged within 24
hours of surgery. The urethral catheter was removed at a
mean time of 8.9 days (range, 1 to 29). At a mean fol-
low-up of 11 months, 96% of patients (137/143) had a
PSA0.2 ng/mL. Four patients had postoperative compli-
cations including an ileus,2 small bowel obstruction1 re-
quiring reoperation, and a urethral stricture1 requiring
repeat dilatation.
Table 4 outlines the postoperative pathology data across
our cohort of patients. Two patients (1%) did not have any
tumor identifiable in the final pathology specimen, 1 of
whom received preoperative hormonal deprivation ther-
apy. Organ-confined (OC) disease (pT2) was present in
122/141 patients (87%) and extracapsular extension (ECE)
was present in the final pathology analysis (pT3/T4) of
19/141 (13%) patients. Twenty-four of 141 men (17%) in
our series had a positive margin on examination of the
specimen, with a decrease from 23% (16/70) to 11% (8/70)
when comparing our more recent 70 patients with the
initial 70 (P0.07). Patients with ECE had a significantly
higher rate of positive surgical margins than did those
with OC disease (47% vs 12%, P0.001). When exclu-
sively considering pT3 disease, we further noted a de-
crease in positive margins when comparing our first 70
patients (5/9; 56%) with our latter 70 (2/8; 25%). No
significant difference existed in positive margin rates in
the Gleason 7 cohort (19/122, 16%) and the Gleason 7
group (4/19, 21%) (P0.55). Over 40% (14/33) of the
positive margins were located in the posterior aspect of
Table 1.
Demographic Data
No. Patients 143
Age (range) 60.4 (43–75)
BMI (kg/m
2) (range) 26.8 (18–38)
Serum PSA (ng/mL) (range) 6.7 (1–60)
Gleason Score (%)
5 1 (1)
6 75 (52)
7 53 (37)
8 9 (6)
9 5 (4)
No. Clinical Stage (%)
T1c 97 (67)
T2a 44 (31)
T2b 2 (2)
Family History of Prostate Cancer (%) 16 (11)
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posterior positive margins remained unchanged as expe-
rience matured in this series; however, margin positivity at
the bladder neck decreased from 7 in the first cohort of
patients to 2 in our latter operative experience.
Figure 1 graphically depicts the return of full urinary
continence across the entire cohort. Patients requiring no
urinary pads were considered continent, and the use of
even one pad per day for occasional stress urinary incon-
Table 3.
Postoperative Data
Mean Follow-up (mos) (range) 11 (3–26)
Hospitalization Days (range) 1.8 (1–10)
First 70 1.9 (1–10)
Second 70 1.1 (1–7)
Days Foley Catheterization
(range)
8.9 (1–29)
Postop PSA 0.2 ng/mL
(%)
96
Postop Complications (%)
Ileus 2 (1)
Bowel obstruction 1 (1)
Urethral stricture 1 (1)
Table 2.
Operative Data
P Value*
Operative Duration (mins) (range)
Overall 241 (120–540) 0.001
First 70 318 (150–540)
Second 70 209 (120–474)
Estimated Blood Loss (mL) (range)
Overall 274 (10–1800) 0.001
First 70 387 (50–1800)
Second 70 155 (10–600)
Nerve Sparing
† (%)
Bilateral 109 (86)
Unilateral 13 (10)
Non-nerve sparing
‡ 5 (4)
Open Conversions (%)
Overall 5 (3) 0.17
First 70 4 (6)
Second 70 1 (1)
*Comparison of first 70 cases versus second 70 cases in series.
†Data available for 127 patients.
‡Two of these 5 patients underwent robotic genitofemoral nerve
grafts.
Table 4.
Pathologic Data
Pathologic Stage
T0 (no tumor) 2 (1)
T2a 15 (10)
T2b 24 (17)
T2c 83 (58)
T3a 12 (8)
T3b 5 (3)
T4 2 (1)
Gleason Score (%)
P0 (no tumor) 2 (1)
5 1 (1)
6 43 (30)
7 78 (55)
8 8 (6)
9 11 (8)
Perineural Invasion (%) 38 (27)
No. Positive Margins (%)
Overall 24 (17)
First 70 16 (23)
Second 70 8 (11)
Location Total (1st 70/2nd 70)*
Apex 5 (2/3)
Bladder neck 9 (7/2)
Anterior 5 (3/2)
Posterior 14 (7/7)
Pos. Margins by Stage (%)
pT2a 2/15 (13)
pT2b 0/24 (0)
pT2c 13/83 (16)
pT3a 5/12 (42)
pT3b 2/5 (40)
pT4 2/2 (100)
Pos. Margins by Gleason (%)
7 19/122 (16)
7 4/19 (21)
*Total number of positive margin sites identified in all speci-
mens. Several patients had more than 1 site of positive margins.
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our analysis. The median time to complete continence
was 3.5 months, and over 95% of patients were fully
continent at 1-year follow-up. Because our data are await-
ing maturity, we will hold off on reporting potency data in
this analysis.
DISCUSSION
As robotic surgery becomes a more accepted treatment
modality for clinically localized prostate cancer, many
urologists are struggling to incorporate this technique into
their therapeutic armamentarium. Increasingly, surgeons
are foregoing open retropubic approaches with a techni-
cally challenging robotic-assisted technique for which ef-
ficacy data are currently limited but growing. It is the
intent of our analysis to objectively analyze the robotic
approach from an oncologic standpoint, and in doing so,
to characterize the oncologic and therapeutic efficacy of
this relatively new and growing technology.
Although the ultimate measure of any intervention is the
ability to prolong long-term survival, modifications in sur-
gical technique can be assessed in the short-term by an-
alyzing pertinent oncological principles. One such vari-
able is pathology margin status. It is generally agreed that
a positive margin is indicative of incomplete tumor resec-
tion and bears significant prognostic importance. Several
institutions have demonstrated the independent prognos-
tic significance of positive surgical margins across all
stages of disease.13–15 Han et al16 further point out that the
rate of positive surgical margins has declined dramatically
from around 40% during the early 1980s to less than 10%
more recently. Although these observations are likely mul-
tifactorial, the lower positive margin rates over the past
decade are largely attributable to the stage migration that
has occurred in the era of PSA screening. It is imperative,
however, to also consider contemporary refinements in
preoperative planning, biopsy strategies, and surgical
technique.17 As we embark on the robotic age for the
treatment of prostate cancer, it is essential that we adhere
to surgical principles learned over the last 3 decades.
In this study, we report an overall positive margin rate of
17%. During the first half of our experience, we noted a
23% positive margin rate, which declined to 11% over our
last 70 consecutive patients. Further, no difference existed
in the pathologic distribution of tumors between our ini-
tial 70 patients and our latter 70 (9 vs 10 cases of ECE).
Collectively, these data suggest that the decline in the
positive margin rate is most attributable to an improved
surgical skill set in the robotic technique rather than a
decrease in the number of biologically aggressive tumors.
Figure 1. Time to full continence.
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incidence of positive margins when comparing specimens
with organ-confined disease with those with extracapsular
extension (12% vs. 47%, P0.001). Noteworthy, however,
is the decrease in positive margin rates from 56% to 25% in
the pT3 subgroup of tumors during the evolution of our
experience. This underscores that robotic prostatectomy is
a reasonable surgical alternative for organ-confined, as
well as pT3 disease. Thus, even in our initial robotic
experience, the results compare favorably with those of
other reported robotic series, as well as with the current
oncologic gold standard open retropubic approach.18,19
The specific location of positive margins is explainable
both by surgical experience and technique. As depicted in
Table 4, bladder neck positive margins declined over
3-fold when comparing the first half of our robotic expe-
rience and our most recent surgical series. The antegrade
approach utilized during a robotic prostatectomy can be
quite challenging and choosing the appropriate location
for incision of the bladder neck can be difficult. As our
experience in robotic surgery has matured, we have
learned to take a wider bladder neck and robotically
reconstruct the bladder as necessary. This modification
has probably resulted in decreased positive bladder neck
margins as our experience increased. In terms of the
anterior and apical margins, we noted that 15% (5/33) of
all positive margin sites were at each of these 2 anatomic
locations, respectively. This compares favorably with
other published reports in which the apical positive mar-
gin rates range from 5% to 28%.20 We believe that the
anterior and apical dissection is enhanced with the robotic
approach likely due to the use of an angled lens resulting
in improved visualization of the dorsal vein/urethral com-
plex.
At 1-year follow-up, 97% (139/143) of men were fully
continent without the requirement of any pads. This com-
pares favorably with continence data published following
the open retropubic approach. Our 3-month follow-up
data, however, indicate that less than 50% of patients are
fully continent at this time point. Anecdotally, this is lower
than the continence rates we have observed for our con-
temporary open retropubic prostatectomy series. One
possible explanation is that the enhanced robotic visual-
ization may result in excessive dissection of the striated
sphincter complex beyond the apex of the prostate. To
improve the early continence rates, we have made several
modifications in our current technique including tacking
the urethra to the periosteum of the pubis and avoiding
excessive dissection beyond the apex of the prostate. With
such modifications, our short-term continence rates have
improved in a more contemporary group of patients (data
not shown).
CONCLUSION
Robotic-assisted radical prostatectomy is an effective mo-
dality for the treatment of clinically localized prostate
cancer. We acknowledge that a learning curve needs to be
overcome; however, with a rigorous, focused robotic ed-
ucational program, early oncologic functional results com-
pare favorably with results of the open retropubic ap-
proach.
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